Shanghai Pharmaceuticals Holding Co.,Ltd. (601607), through its wholly-owned subsidiary Shanghai Shang Yao Xinyi Pharmaceutical Factory Co., Ltd., publicly listed the transfer of its 51% stake in Gansu Xinyi Tiansen Pharmaceutical Co., Ltd. and corresponding debt claims on September 24, 2025. The transfer reserve price is set at 48.1088 million yuan, with the information disclosure period ending on October 28, 2025.

The target company, Gansu Xinyi Tiansen Pharmaceutical Co., Ltd., was established on May 12, 1997, with a registered capital of 61.6667 million yuan. Its business scope includes pharmaceutical production, pharmaceutical wholesale, and primary agricultural product procurement. The equity structure shows that Shanghai Shang Yao Xinyi Pharmaceutical Factory Co., Ltd. currently holds 51%, Du Yuting holds 32.43%, and Shi Fangju holds 16.57%.

The target company's financial performance has been poor. According to disclosed information, Xinyi Tiansen Pharmaceutical recorded operating revenue of 2.028 million yuan in 2024, with a net loss of 12.72 million yuan. Entering 2025, operating conditions have not improved, with zero operating revenue in the first eight months and a net loss of 5.5994 million yuan. As of the end of August 2025, the company's total assets amounted to 78.2371 million yuan, with total liabilities of 17.7193 million yuan.

This transfer includes the 51% equity stake and the transferor's 8.2203 million yuan debt claim against the target company. The transaction sets certain conditions for potential buyers, such as not accepting joint buyers or trust arrangements for bidding, requiring proper arrangement for the target company's employees, and committing not to use Shanghai Pharmaceuticals' related trade names and intangible assets after the transaction completion.

Data shows that Shanghai Pharmaceuticals recorded non-recurring adjusted net profit of 2.1 billion yuan in the first half of 2025, down 22.38% year-on-year. In the secondary market, the stock closed at 17.91 yuan on September 25, with a total market capitalization of 66.417 billion yuan.